Artal Group S.A. Albireo Pharma, Inc. Transaction History

Artal Group S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$23.94 - $33.74 $14.4 Million - $20.2 Million	-600,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$32.03 - $42.85 $3.2 Million - $4.29 Million	-100,000 Reduced 14.29%	600,000 $21.2 Million
Q4 2020 Feb 11, 2021	SELL	$31.56 - $42.16 $4.78 Million - $6.38 Million	-151,405 Reduced 17.78%	700,000 $26.3 Million
Q3 2020 Nov 13, 2020	BUY	$23.19 - $41.61 $8.14 Million - $14.6 Million	351,045 Added 70.16%	851,405 $28.4 Million
Q2 2020 Aug 14, 2020	SELL	$14.82 - $29.92 $1.3 Million - $2.63 Million	-87,765 Reduced 14.92%	500,360 $13.3 Million
Q1 2020 May 14, 2020	BUY	$11.67 - $27.23 $1.61 Million - $3.76 Million	137,925 Added 30.64%	588,125 $9.63 Million
Q3 2019 Nov 14, 2019	BUY	$20.0 - $31.88 $4,000 - $6,376	200 Added 0.04%	450,200 $9 Million
Q2 2019 Aug 09, 2019	SELL	$30.67 - $37.86 $1.53 Million - $1.89 Million	-50,000 Reduced 10.0%	450,000 $14.5 Million
Q2 2018 Aug 10, 2018	SELL	$28.9 - $37.31 $1.38 Million - $1.78 Million	-47,841 Reduced 8.73%	500,000 $17.8 Million
Q1 2018 May 10, 2018	BUY	$26.78 - $39.35 $6.64 Million - $9.75 Million	247,841 Added 82.61%	547,841 $17.8 Million
Q4 2017 Feb 09, 2018	BUY	$21.56 - $28.14 $6.47 Million - $8.44 Million	300,000	300,000 $7.68 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.